What is Halozyme Therapeutics?
Halozyme Therapeutics is a biopharmaceutical company dedicated to enhancing patient experiences and outcomes through disruptive therapeutic solutions. At the core of its innovation is the ENHANZE® drug delivery technology, powered by the proprietary enzyme rHuPH20. This commercially-validated platform enables the subcutaneous delivery of injected drugs and fluids, aiming to revolutionize treatment by offering rapid delivery and reducing the overall burden on patients. Beyond its drug delivery technology, Halozyme also develops, manufactures, and commercializes drug-device combination products, including advanced auto-injector technologies. These products are designed to offer commercial and functional advantages such as improved convenience, reliability, and tolerability, ultimately enhancing patient comfort and adherence. The company's portfolio includes two proprietary commercial products, Hylenex® and XYOSTED®, alongside partnered commercial products and ongoing development programs with major pharmaceutical entities like Teva Pharmaceuticals and Idorsia Pharmaceuticals.
How much funding has Halozyme Therapeutics raised?
Halozyme Therapeutics has raised a total of $1.1B across 10 funding rounds:
Corporate Investment
$5.5M
Stock Offering
$38.2M
Stock Offering
$60M
Stock Offering
$81.8M
Debt
$50M
Stock Offering
$107.8M
Debt
$150M
Stock Offering
$135M
Debt
$400M
Corporate Investment (2009): $5.5M led by Baxter Healthcare Corporation
Stock Issuance/Offering (2009): $38.2M supported by Undisclosed
Stock Issuance/Offering (2010): $60M featuring Undisclosed
Stock Issuance/Offering (2012): $81.8M backed by Undisclosed
Debt (2014): $50M with participation from Silicon Valley Bank and Oxford Finance
Stock Issuance/Offering (2014): $107.8M led by Undisclosed
Debt (2016): $150M supported by Pharmakon Advisors and Athyrium Capital Management
Stock Issuance/Offering (2017): $135M featuring Undisclosed
Debt (2019): $400M backed by Undisclosed
Key Investors in Halozyme Therapeutics
Silicon Valley Bank
Silicon Valley Bank, founded in 1983, is a financial institution offering a comprehensive suite of commercial and private banking services, asset management, and investment services, with a strong focus on the technology and healthcare sectors.
Oxford Finance
Oxford Finance, established in 2002, is a specialty finance firm providing flexible financial solutions tailored to the unique needs of companies within the healthcare and life sciences industries worldwide.
Athyrium Capital Management
Athyrium Capital Management is a prominent investment firm specializing in structured investments within the global healthcare sector, offering financing solutions across pharmaceuticals, biotechnology, and healthcare services.
What's next for Halozyme Therapeutics?
The recent major strategic investment in Halozyme Therapeutics, amounting to $400M, positions the company for accelerated growth and expanded market penetration. This substantial backing, within the context of its overall enterprise-level funding of $1.1B, suggests a strategic phase focused on scaling operations, further research and development, and potentially broader commercialization of its ENHANZE® technology and auto-injector platforms. The company's trajectory indicates a strong emphasis on strategic partnerships and the continued refinement of its drug delivery systems to address unmet needs in the biopharmaceutical landscape. Future developments are likely to center on leveraging these financial resources to solidify its market position and drive innovation in patient-centric therapeutic solutions.
See full Halozyme Therapeutics company page
